The purposes of this study are to test whether the addition of cisplatin to single agent chemotherapy (either gemcitabine or pemetrexed) prolongs survival in elderly patients with non squamous non small cell lung cancer (NSCLC), and to test whether pemetrexed prolongs survival as compared to gemcitabine in elderly patients with non squamous NSCLC.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
232
overall survival
factorial design with two comparisons: single agent chemotherapy versus chemotherapy plus cisplatin (Arms A+C versus Arms B + D), and gemcitabine versus pemetrexed (Arms A+B versus Arms C+D)
Time frame: one year
worst grade toxicity per patient
according to Common Toxicity Criteria for Adverse Events v. 4.03
Time frame: evaluated at end of each 3 week cycle of chemotherapy up to 18 weeks
progression free survival
Time frame: 6 months
changes in quality of life
Time frame: baseline and up to 18 weeks
objective response
Time frame: after 9 and 18 weeks of therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ospedale San Lazzaro
Alba, Italy
Ospedali Riunit Umberto I-Lancisi-Salesi
Ancona, Italy
Oncologia Universitaria degli Studi di Roma
Aprilia, Italy
Ospedale Cardinal Massaia
Asti, Italy
S. Giuseppe Moscati
Avellino, Italy
Ospedale Senatore Antonio Perrino
Brindisi, Italy
Univeristaria Policlinico Monserrato di Cagliari
Cagliari, Italy
Ospedale A. cardarelli
Campobasso, Italy
U.L.S.S. 15 Veneto
Camposampiero, Italy
Ospedale Ramazzini di Carpi
Carpi, Italy
...and 38 more locations